Zacks.com on MSN3h
FATE Presents Encourgaing Data From Lupus Study, Stock GainsFate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in ...
The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...
Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here ...
After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...
T cell therapy for autoimmune diseases, showing clinical responses in seven lupus patients. The therapy uses the same ...
Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...
Live Science on MSN7h
'Like a reset button on a computer': Designer cells 'reboot' immune system in 3 different autoimmune diseasesA small trial used designer CAR T cells to reboot the immune systems of patients with three autoimmune diseases, but it's ...
Lupus is a condition often shrouded in mystery. Presenting with a huge range of symptoms, it’s tricky to diagnose, tough to ...
A greater response was observed across multiple clinical endpoints among participants treated with DZP, including 50% less severe disease flares compared to participants on standard of care alone." ...
Artificial intelligence is making impressive strides in its ability to read medical images. In a recent test in Britain's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback